imiquimod has been researched along with fingolimod hydrochloride in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
| Dietert, JB; Hurst, EA; Singla, P | 1 |
| Corbett, A; Kermode, AG; Reddel, SW; Triplett, J | 1 |
| Asano, Y; Kamata, M; Mitsui, A; Okura, I; Sato, S; Shimizu, T; Tada, Y | 1 |
4 other study(ies) available for imiquimod and fingolimod hydrochloride
| Article | Year |
|---|---|
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |
Cells to Surgery Quiz: January 2018.
Topics: Administration, Cutaneous; Arm; Arm Injuries; Bleomycin; Botulinum Toxins, Type A; Cicatrix, Hypertrophic; Dermatologic Agents; Fingolimod Hydrochloride; Fluorouracil; Humans; Imiquimod; Signal Transduction; Skin | 2018 |
Warts and all: Fingolimod and unusual HPV-associated lesions.
Topics: Ankle; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cryotherapy; Fingers; Fingolimod Hydrochloride; Foot Dermatoses; Hand Dermatoses; Humans; Imiquimod; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Warts | 2019 |
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Interleukin-17; Intraepithelial Lymphocytes; Langerhans Cells; Lymph Nodes; Mice; Psoriasis; Skin; Up-Regulation | 2021 |